VEGFR-3 inhibitor materials and methods
AssigneeVegenics Limited
InventorsKari Alitalo, Erkki Koivunen, Hajime Kubo
Life of this patent
Estimating the term…
Abstract
The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.
Claims23
An isolated peptide comprising the amino acid sequence set forth in any one of SEQ ID NOs:
- 35-66, wherein the peptide is 8 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
An isolated peptide comprising the amino acid sequence set forth in SEQ ID NO:
- 34, wherein the peptide is 10 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
An isolated peptide comprising the amino acid sequence spanning amino acid residue 2 through amino acid residue 9 of any one of SEQ ID NOs:
- 35 and 55-58, wherein the peptide is 8 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
Dependencies are inferred from the claim text.